Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron: Comparison with other indole-containing 5-HT 3 antagonists

Drug Metabolism and Disposition

Volumn 24, Issue 5, 1996, Pages 602-609

  Sanwald, Patricia ^a   David, Murielle ^a   Dow, James ^a,b  

^a Department of Drug Metabolism   (France)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DEBRISOQUINE; DOLASETRON MESILATE; DRUG METABOLITE; FURAFYLLINE; INDOLE DERIVATIVE; KETOCONAZOLE; ONDANSETRON; SEROTONIN 3 ANTAGONIST; SULFAPHENAZOLE; TROPISETRON;

ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG OXIDATION; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME POLYMORPHISM; HUMAN; HUMAN TISSUE; LIVER MICROSOME; PRIORITY JOURNAL; RACEMIC MIXTURE; VOMITING;

CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP2E1; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; HYDROXYLATION; INDOLES; MALE; MASS SPECTROMETRY; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; MOLECULAR STRUCTURE; ONDANSETRON; OXIDATION-REDUCTION; QUINOLIZINES; SEROTONIN ANTAGONISTS;

EMESIS;

EID: 0029880344     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. 3 receptors. Drug Dev. Res. 28, 87-93 (1993).
2. T. Conroy, P. Cappelare, M. Fabbro, A. A. Fauser, T. A. Splinter, M. Spielmann, M. Scheider, B. Chevalier, A. Goupil, and J. Chauvergne: Acute antiemetic efficacy and safety of dolasetron mesylate, a 5-HT3 antagonist, in cancer patients treated with cisplatin. Am. J. Clin. Oncol. 17, 97-102 (1994).
3. H. Boxenbaum, T. Gillespie, K. Heck, and W. Hahne: Human dolasetron pharmacokinetics. I. Disposition following single dose intravenous administration to normal male subjects. Biopharm. Drug Dispos. 13, 693-701 (1992).
4. H. Boxenbaum, T. Gillespie, K. Heck, and W. Hahne: Human dolasetron pharmacokinetics. II. Absorption and disposition following single dose oral administration to normal male subjects. Biopharm. Drug Dispos. 14, 131-141 (1993).
5. J. Dow and C. Berg: Stereoselectivity of the carbonyl reduction of dolasetron in rats, dogs and humans. Chirality 7, 342-348 (1995).
6. M. K. Reith, G. A. Leeson, and L. K. Cheng: Identification of enzymes responsible for dolasetron metabolism using human hepatic cytosol and characterized human liver. ISSX Proc. 6, 254 (1994).
7. 3 receptor antagonists, a new approach in emesis: a review of ondansetron, granisetron and tropisetron. Anticancer Drugs 2, 343-355 (1991).
8. K. M. Bruijn: Tropisetron - a review of clinical experience. Drugs 43 (Suppl. 3), 11-22 (1992).
9. B. J. Chaffee and R. M. Tankanow: Ondansetron - the first of a new class of antiemetic agents. Clin. Pharmacol. 10, 430-446 (1991).
10. U. A. Meyer: Genetic polymorphisms of drug metabolism. Fundam. Clin. Pharmacol. 4, 595-615 (1990).
11. V. Fischer, A. E. M. Vickers, F. Heitz, S. Mahadevan, J. Baldeck, P. Minery, and R. Tynes: The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron, and ondansetron. Drug Metab. Dispos. 22, 269-274 (1994).
12. L. Firkusny, H. K. Kroemer, and M. Eichelbaum: In vitro characterization of cytochrome P450 catalysed metabolism of the antiemetic tropisetron. Biochem. Pharmacol. 49, 1777-1784 (1995).
13. B. M. Kerr, S. Y. Boulding-Brown, C. A. Lee, C. C. Boehlert, J. F. Pritchard, C. M. Dixon, P. V. Colthup, M. K. Bayliss, M. H. Tarbit, and C. J. Serabjit-Singh: Cytochrome P-450 metabolism of ondansetron by CYP1A2, CYP1A1 and CYP2D6. ISSX Proc. 4, 137 (1994).
14. A. C. Gough, J. S. Miles, N. K. Spurr, J. E. Moss, A. Gaedigk, M. Eichelbaum, and C. W. Wolf: Identification of the primary gene defect at the cytochrome P-450 CYP2D6 locus. Nature 347, 773-776 (1990).
15. M. M. Bradford: A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254 (1976).
16. T. Omura and R. Sato: The carbon monoxide-binding pigment of liver microsomes. J. Biol. Chem. 239, 2370-2385 (1964).
17. S. Kobayashi, S. Murray, D. Watson, D. Sesardic, D. S. Davies, and A. R. Boobis: The specificity of inhibition of debrisoquine 4-hydroxylase activity by quinidine and quinine in the rat is inverse of that in man. Biochem. Pharmacol. 38, 2797-2799 (1989).
18. M. Maurice, L. Pichard, M. Daujat, I. Fabre, H. Joyeux, J. Domergue, and P. Maurel: Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. FASEB 6, 752-758 (1992).
19. D. J. Back, J. F. Tjia, J. Karbwang, and J. Colbert: In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines. Br. J. Clin. Pharmacol. 26, 23-29 (1988).
20. S. E. Clarke, A. D. Ayrton, and R. J. Chenery: Characterization of the inhibition of P4501A2 by furafylline. Xenobiotica 24, 517-526 (1994).
21. F. P. Guengerich, D. Kim, and M. Iwasaki: Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem. Res. Toxicol. 4, 168-179 (1991).
22. P. Sanwald, N. D. Huebert, and K. D. Haegele: Simultaneous measurement of the major metabolites of dolasetron mesilate in human urine using solid-phase extraction and high-performance liquid chromatography. J. Chromatogr. B. 661, 101-107 (1994).
23. P. Sanwald, M. David and J. Dow: The use of electrospray ionization-liquid chromatography-mass spectometry to study the role of CYP2D6 in the in vitro metabolism of 5-hydroxytryptamine receptor antagonists. J. Chromatogr. B. in press.
24. 3 receptor antagonist Drug Metab. Dispos. 23, 806-812 (1995).
25. P. Jenner, J. W. Gorrod, and A. H. Beckett: The absorption of nicotine-1-N-oxide and its reduction in the gastro-intestinal tract in man. Xenobiotica 3, 341-349 (1977).
26. G. Powis, M. M. Ames, and J. S. Kovach: Metabolic conversion of indicine N-oxide to indicine in rabbits and humans. Cancer Res. 39, 3564-3570 (1979).
27. M. Al-Waiz, R. Ayesh, S. C. Mitchell, J. R. Idle, and R. L. Smith: Disclosure of the metabolic retroversion of trimethylamine N-oxide in humans: a pharmacogenetic approach. Clin. Pharmacol. Ther. 42, 608-612 (1987).
28. D. J. Newton, R. W. Wang, and A. Y. H. Lu: Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab. Dispos. 23, 154-158 (1995).
29. J. C Bloomer, S. J. Baldwin, G. J. Smith, A. D. Ayrton, S. E. Clarke, and R. J. Chenery: Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of granisetron. Br. J. Clin. Pharmacol. 38, 557-566 (1994).
30. E. I. L. Ashford, J. L. Palmer, A. Bye, and A. Bedding: The pharmacokinetics of ondansetron after intravenous injection in healthy volunteers phenotyped as poor or extensive metabolisers of debrisoquine. Br. J. Clin. Pharmacol. 37, 389-391 (1994).
31. N. D. Huebert, J.-J. Schwartz, C. Hinze, and K. D. Haegele: Bioavailability and the effect of food on the pharmacokinetics of dolasetron mesilate and its active metabolite, MDL74156, in man. Br. J. Clin. Pharmacol. 37, 120P (1994).
32. G. T. Tucker: Clinical implication of genetic polymorphism in drug metabolism. J. Pharm. Pharmacol. 46 (Suppl. 1), 417-424 (1994).
33. J. F. Pritchard: Ondansetron - metabolism and pharmacokinetics. Semin. Oncol. 19 (Suppl. 4), 9-15 (1992).